Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens

NCT00090038 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00090038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00090038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens
Lead sponsor
Biogen
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2003
Completion date
November 30, 2007
Enrollment
168 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma